Dexcom rises after raising annual revenue forecast

Including the session's move, the stock is up about 25% year to date.

Dexcom reported second-quarter revenue of $1.31 billion, above analysts' average estimate of $1.29 billion, according to data compiled by LSEG.

The company also posted adjusted profit of 70 cents per share, compared with analysts' estimate of 61 cents.

Shares of medical device maker Dexcom rose 10% to $82.47 after the company on Thursday raised its annual revenue forecast on sustained demand for its continuous glucose monitors, devices that track blood sugar levels without finger-prick tests.

Dexcom now sees full-year revenue of $5.18 billion-$5.25 billion, versus its prior forecast of $5.16 billion-$5.25 billion. Analysts expect $5.22 billion.